Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. million price point per dose.

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

ACRP blog

APRIL 5, 2023

The life sciences sector is increasingly leveraging technology across its operations, and this trend will continue in 2023 with more collaborations and partnerships between pharmaceutical, biotechnology, and medical device companies and information technology vendors, Lyons adds.

Big Data 52

Big Data Clinical Trials Clinical Trials Life Science 52

Drug Discovery World

DECEMBER 20, 2022

As 2022 draws to a close, life sciences market analysts attempt to correctly predict what the next 12 months might bring to the drug discovery sector. In summary, 2023 could be a very exciting year for life sciences. DDW’s Diana Spencer summarises the key trends likely to impact the market in 2023. .

Drugs 52

Drugs Gene Editing Clinical Trials Clinical Trials 52

XTalks

MAY 9, 2024

First, the integration of AI, big data and high-performance computing has the potential to not only expedite the drug discovery process, but also could contribute to better understanding of diseases at the molecular level. Tahi Ahmadi: Two key areas where we anticipate breakthroughs are technological advancements and new modalities.

Antibody 52

Antibody Clinical Trials Clinical Trials Medicine 52

The Pharma Data

JULY 12, 2021

The study findings could measurably change how researchers sift through big data to find meaningful information with significant benefit to patients, the pharmaceutical industry and the nation’s health care systems. have access to unlimited amounts of ‘big data’ and better tools than ever to analyze such data. .”

Drugs 52

Drugs Gene Expression Big Data Gene 52

pharmaphorum

JULY 4, 2022

A very important question was raised by the webinar attendee of the diversity and inclusion of patients in clinical research, and Dr Hackett commented: “A lot of the work has been done in our Paediatric & Rare Disease network, as well as our Cell and Gene Therapy network, we are tackling the issue of diversity in data.

Genome 105

Genome Genomics Research Medicine 105

XTalks

AUGUST 2, 2023

Meanwhile, BioMarin’s gene therapy Roctavian is approved by the FDA for the treatment of hemophilia A. Onureg (azacitidine), a leukemia therapy, also saw large growth of 70 percent to $124 million in 2022, and the multiple sclerosis drug Zeposia (ozanimod) generated $250 million in 2022, an 87 percent increase. billion ($19.19

Sales 98

Sales Manufacturing FDA Approval Life Science 98